BACKGROUND: Circulating microRNAs (miRNAs) are emerging as promising biomarkers for cancer. The objective of the current study was to investigate the potential of circulating cell-free miRNAs as biomarkers for colorectal cancer (CRC) and its precursor lesion, colorectal adenoma. METHODS: The serum levels of 800 miRNAs were assessed in a discovery set of 21 patients with CRC, 19 patients with adenoma, and 21 healthy controls using the NanoString miRNA analysis platform. Significantly differentially expressed miRNAs were examined further in a validation cohort of 34 patients with CRC, 33 patients with adenoma, and 35 healthy controls using Fluidigm quantitative polymerase chain reaction assays. RESULTS: The ratios between the expression values of the differentially expressed miRNAs were computed. Three miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR135b, and miR-451a/miR-491-5p) were validated for discriminating patients with adenoma and those with CRC from the healthy control group, and 5 miRNA ratios (let-7b/ miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p) were validated for discriminating patients with CRC from those with adenoma and healthy controls. The area under the receiver operating characteristic curve values for the 3 miRNA ratios in discriminating patients with adenoma from healthy controls were 0.831 and 0.735, respectively, in the discovery and validation sets. The area under the receiver operating characteristic curve values for the 5 miRNA ratios in discriminating patients with CRC from those with adenoma were 0.797 and 0.732, respectively, in the discovery and validation sets. Pathway analysis revealed that target genes regulated by the miRNAs from the miRNA ratios were enriched mainly in metabolismrelated and inflammation-related pathways. CONCLUSIONS: The data from the current study suggest that circulating miRNAs can distinguish patients with CRC and those with adenoma and may represent novel biomarkers for the early, noninvasive detection of CRC. Cancer 2018;124:785-96. V C 2017 American Cancer Society.
INTRODUCTION
Colorectal cancer (CRC) poses a significant threat to the health of global populations. In the United States, CRC is the second leading cause of cancer-related deaths, with >50,000 deaths reported annually. 1 CRC often develops in a progressive fashion from normal colon epithelial cells to benign adenomas, and ultimately to malignant cancer lesions. The progression of CRC has been associated with sequential changes in genes such as KRAS, DCC, APC, and TP53. 2 The 5-year survival rate for patients with early-stage CRC is nearly 90%, but only approximately 39.6% of CRC tumors are diagnosed at an early stage. 3 Thus, in the majority of patients, CRC could be cured if it were detected and resected at a precancerous or early stage. Therefore, the early detection of CRC and colorectal adenoma is one of the main prerequisites for the successful treatment and reduction of mortality from CRC.
To the best of our knowledge, there currently are few blood-based biomarkers suitable for population screening or the early diagnosis of CRC. CRC screening tests that primarily detect cancer, which include the guaiac-based fecal occult blood test and the fecal immunochemical test-based fecal occult blood test, and testing stool for exfoliated DNA frequently were used in population screening; nevertheless, these tests were insufficiently sensitive and specific for detecting CRC in its early stages. 4, 5 In recent years, methylated SEPT9 DNA has been found to be a sensitive and specific biomarker for the detection of CRC from blood and is available as the Epi proColon test (Epigenomics Inc, Seattle, Washington), which was clinically approved as an aid in the detection of CRC. 6 Nevertheless, the test's overall sensitivity of approximately 70% and specificity of 80% indicate there is still room for improvement. In addition, endoscopic and radiologic examinations, including flexible sigmoidoscopy, colonoscopy, double-contrast barium enema, and computed tomography colonography (or virtual colonoscopy) can detect cancer and advanced precursor lesions, but their widespread use is limited by their invasive nature and high costs. 4, 7 Therefore, there is a great need for a cost-effective and noninvasive biomarker-based test for the early detection of CRC.
MicroRNAs (miRNAs) are small, 19-nucleotide to 25-nucleotide noncoding RNAs that negatively regulate the expression of their targeted genes at the posttranscriptional level by base-pairing to the complementary sites on the target messenger RNAs (mRNAs). They play an important regulatory role in a wide range of biological and pathological processes and are involved in cancer development. 8, 9 MiRNAs frequently are dysregulated in cancer and have shown great potential as tissue-based markers for cancer classification and prognostication. 10, 11 Because some miRNAs also are secreted into the blood as cell-free miRNAs, which can be detected in serum in highly stable form, circulating miRNAs are emerging as promising, minimally invasive biomarkers for diagnosing and monitoring human cancers. 12, 13 In the past few years, researchers have investigated the potential of using miRNAs as novel serum-based/ plasma-based biomarkers for the early noninvasive or minimally invasive diagnosis of CRC. Several studies have examined the differences in circulating miRNA expression between patients with CRC and healthy controls, with a few miRNAs consistently shown to be differentially expressed in patients with CRC, such as upregulation of miRNA-21 and miR-92a-3p and downregulation of miR-422a. [14] [15] [16] In addition, some studies have demonstrated the deregulated expression of selected miRNAs in patients with different types of adenoma. [17] [18] [19] However, to the best of our knowledge, those studies were limited by 1 of the following factors: insufficient number of screened miRNAs, small sample size, lack of independent validation, and failure to differentiate patients with adenoma from those with CRC and healthy controls.
In this 2-phase study, we performed global miRNA profiling using the NanoString platform (NanoString Technologies Inc, Seattle, Washington) with validation using targeted real-time polymerase chain reaction (PCR) Taqman assay (Applied Biosystems Inc, Foster City, California) to characterize the miRNA expression profile in large sets of serum specimens from patients with colon cancer or adenoma as well as from healthy controls. We aimed to identify miRNAs that could potentially serve as novel serum-based biomarkers for CRC screening or early detection.
MATERIALS AND METHODS

Patient Cohorts and Sample Collection
Two separate patient cohorts were selected for the current study: a discovery set (61 patients), comprising 21 healthy control participants, 19 patients with adenoma, and 21 patients with CRC for miRNA profile screening; and a validation set (102 patients) comprising 35 healthy controls, 33 patients with adenoma, and 34 patients with CRC. All patients with adenoma did not have a prior or incident diagnosis of CRC or a familial form of adenoma. The patients with adenoma and CRC had received no chemotherapy or radiotherapy; their disease was histologically confirmed at The University of Texas MD Anderson Cancer Center in Houston and they were recruited at the center between 2009 and 2014. Control subjects with no cancer history were recruited from the general population of Houston, Texas by random telephone digit dialing during the same period. Controls were frequency-matched to patients with CRC and adenoma by sex, age, ethnicity, and residence during the same period. Participants were selected at random for the discovery set versus the validation set. The study was approved by The University of Texas MD Anderson Cancer Center institutional review board, and all study participants signed an approved informed consent form according to institutional guidelines.
Blood samples were collected according to standard phlebotomy procedures. A total of 10 mL of whole blood from each participant was collected into tubes and immediately placed on ice. Blood samples were subjected to centrifugation at 1000 3 g for 10 minutes at 48C to spin down the blood cells. The serum supernatant fluid was removed by pipette from the cellular material and then aliquoted and stored in liquid nitrogen tanks until assays were performed.
MiRNA Profiling
Total RNAs were isolated from 750-lL serum samples using a miRNeasy Mini Kit (Qiagen, Germantown, Maryland). The concentration and purity of each RNA sample was evaluated by the NanoDrop ND-100 Spectrophotometer (Thermo Scientific, Wilmington, Delaware) Expression profiles of the top 800 highly curated human miRNAs preselected from miRBase 21 by the manufacturer were measured in the discovery set using NanoString nCounter assays (NanoString Technologies) and performed by the Genomic and RNA Core Service of Baylor College of Medicine in accordance with the manufacturer's instructions. In brief, the prepared RNA samples were ligated with a specific DNA tag onto the 3 0 end of each RNA species. These tags were designed to normalize the melting temperatures of the miRNAs and provided a Original Article unique identification for each miRNA species in the sample. After hybridization and the removal of excess capture and reporter probes, the purified ternary complexes were bound to the imaging surface before they were elongated and immobilized. The surface then was imaged using the nCounter digital analyzer (NanoString Technologies Inc). The expression levels were normalized using the average of expression of the top 100 most-expressed miRNAs in all samples. MiRNAs detected in at least 80% of the serum samples were considered for further analysis. A total of 93 miRNAs were significantly differentially expressed in the healthy control, adenoma, and CRC groups in the discovery set. The ratios of the expression values of each value of a single miRNA compared with the values of all of the other miRNAs were computed. Of these, 191 miRNA ratios were found to be significantly different between the healthy control, adenoma, and CRC groups in the discovery set. Purified RNA samples were reverse-transcribed with a TaqMan miRNA Reverse Transcription Kit (Applied Biosystems), using 150 ng of total RNA and pools of Megaplex RT primers, followed by a preamplification step with Megaplex PreAmp primers (all primers courtesy of Thermo Fisher Scientific, Waltham, Massachusetts). The expression levels of miRNAs in the validation set were normalized to the spiked-in cel-miR-39 and celmiR-54, and the 2-DDCt method was used for analysis. 20, 21 The ratios of the expression values of each value of a single miRNA compared with the values of all of the other miRNAs were computed.
Pathway Analysis
Potential target genes and pathway enrichment analysis of the potential target genes was conducted with a Web-based analytical tool called miRsystem (http://mirsystem.cgm. ntu.edu.tw/), 22 which offered a comprehensive database of validated miRNA targets from the TarBase database and miRecords and predicted targets from 7 programs.
Statistical Analysis
All statistical analyses were performed using Stata statistical software (version 14.0; Stata Corp LLC, College Station, Texas). The rank sum test was applied to evaluate the differences in the median miRNA expression ratio levels between patients with CRC or adenoma and healthy controls. The combined miRNA risk score for each patient was derived by linear combination of the product of the level of miRNA ratio (1 for high and 0 for low) and its logistic regression corresponding coefficient. All patients were dichotomized by the median risk score, such that individuals with a risk score higher than the median were classified as high risk and those with a risk score lower than the median were classified as low risk. The association between risk score and adenoma or CRC risk was assessed using unconditional multivariable logistic regression models, adjusting for age and sex. Receiver operating characteristic (ROC) curves were constructed, and the area under the ROC curve (AUC) was used to evaluate the diagnostic performance of the selected miRNA ratio panel. All tests were 2-sided, and a P value <.05 was considered to be statistically significant.
RESULTS
Cohort Characteristics
Overall, the current study enrolled a total of 163 individuals: 56 patients with CRC, 52 patients with adenoma, and 55 age-matched and sex-matched healthy controls. The demographic and, if pertinent, clinical characteristics of these groups, including sex, age, smoking status, clinical stage of disease, polyp/tumor location, and histology, stratified by the discovery set and validation set, are summarized in Table  1 . There were no significant differences noted with regard to demographic and clinical characteristics between the patients with CRC, patients with adenoma, and healthy controls in either the validation or discovery groups. The discovery and validation sets were not different with regard to host characteristics except for the location of colorectal adenomas and tumor stage in patients with CRC (Table 1 ) (see Supporting Information Table S1 ). The majority of the patients with adenoma had a histologic diagnosis of tubular adenoma (60%-80%), whereas approximately 50% of the patients with adenoma in the validation set were found to have missing information for adenoma location.
Differentially Expressed miRNA Ratios in the Discovery Set
The use of miRNA ratios has been reported to be an easily applicable method with which to develop clinically useful signatures based on circulating biomarkers due to the lack of a consistent internal standard for normalization. 23 Circulating miRNAs of Colorectal Cancer/Zhang et al Cancer February 15, 2018 Therefore, we computed the ratios of the expression values of 93 miRNAs that were significantly differentially expressed in the healthy control, adenoma, and CRC groups. Each value of a single miRNA was compared with the values of all of the other miRNAs; 2529 ratios were obtained and subsequently used to analyze group differences. Of these, 155 miRNA ratios were found to be significantly different in the CRC and adenoma samples compared with the healthy control samples (see Supporting Information Table S2 ). A total of 36 miRNA ratios were found to be significantly different in CRC samples compared with healthy control and adenoma samples (see Supporting Information Table S3 ).
Validation of miRNA Ratios by qRT-PCR Analysis
The 53 differentially expressed miRNAs represented in these 191 miRNA ratios then were validated in an independent set of serum samples. The ratios between the expression values of these miRNAs were computed and compared. Of these, 3 miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR-135b, and miR-451a/miR-491-5p) were confirmed Original Article to be significantly higher in the patients with adenoma and CRC compared with the healthy controls (Fig. 1) . No significant differences were observed for these 3 miRNA ratios between the adenoma and CRC groups. Five miRNA ratios (let-7b/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/ miR-367-3p) were confirmed to be significantly higher in the CRC group compared with both the adenoma group and the healthy control group (Fig. 2) . No significant differences were observed for these 5 miRNA ratios between the adenoma and healthy control groups.
Prediction of Adenoma and CRC Risks by miRNA Ratio Risk Score
The combined effects of the 3 miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR-135b, and miR-451a/ miR-491-5p) on the risk of adenoma and CRC were investigated by calculating risk scores. ROCs were generated to evaluate the discriminatory power of these miRNA ratios for differentiating between the control and disease groups. As shown in Figure 3 , AUC values for miR-17-5p/miR-135b, miR-92a-3p/ miR-135b, and miR-451a/miR-491-5p in discriminating patients with adenoma from healthy controls were 0.831 (95% CI, 0.706-0.956) for the discovery set and 0.735 (95% CI, 0.619-0.851) for the validation set. Similarly, AUC values for let-7b/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p in discriminating patients with CRC from those with adenoma were 0.797 (95% CI, 0.659-0.935) for the discovery set and 0.732 (95% CI, 0.611-0.851) for the validation set.
Target Genes and Pathway Analysis
To explore the biological mechanisms underlying the role of these miRNAs in CRC progression, we performed target prediction coupled with pathway analysis. Target genes of the 12 miRNAs comprising the validated miRNA ratios were identified by both prediction algorithms and experiment-supported databases. Pathway analysis demonstrated that miR-17-5p, miR-135b, miR92a-3p, miR-451a, and miR-491-5p from the 3 miRNA ratios for discriminating patients with adenoma and those with CRC from the healthy control group were mainly enriched in 14 subcategories and the majority of the pathways were related to metabolism, such as metabolism of amino acids and derivatives, glycerolipid metabolism, integration of energy metabolism, amino sugar and nucleotide sugar metabolism, and tyrosine metabolism. The predicted target genes also were involved in the calcium signaling pathway, the C-MYB transcription factor network, and the lysosome pathway (Table 3) . MiRNAs let-7b, miR-367-3p, miR-130a-3p, miR-409-3p, miR-148-3p, miR-27b, miR-409-3p, and miR-21-5p from the 5 miRNA ratios for discriminating patients with CRC from those with adenoma and healthy controls were mainly enriched in 26 subcategories, 4 of which were inflammation-related pathways, such as the chemokine signaling pathway, the chemokine and the chemokine receptors signaling pathway, and the cytokinecytokine receptor interaction pathway (Table 4 ). The predicted target genes also were involved in several critical pathways such as protein processing, direct P53 effectors, the natural killer T cell pathway, cell cycle checkpoints, and the DNA repair pathway.
DISCUSSION
In the current study, we analyzed a cohort of 163 samples representing healthy control participants, patients with benign adenoma, and patients with CRC in independent discovery and validation sets. This analysis identified 3 miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/ miR-135b, and miR-451a/miR-491-5p) that were found to be significantly upregulated in patients with adenoma compared with the healthy control group. We also identified 5 miRNA ratios (let-7b/miR-367-3p, miR-130a-3p/ miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p) that were Abbreviations: 95% CI, 95% confidence interval; CRC, colorectal cancer; miRNA, microRNA; OR, odds ratio. a Risk score from miR-17-5p/miR-135b, miR-92a-3p/miR-135b, and miR-451a/miR-491-5p ratios. b Adjusted by age and sex. c Risk score from let-7b/miR-367-3p, miR-21-5p/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148a-3p/miR-409-3p, and miR-148a-3p/miR-27b ratios.
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Cancer February 15, 2018 significantly upregulated in patients with CRC compared with the patients with adenoma and healthy controls and were effective at distinguishing patients with CRC from those with benign adenoma and the healthy control group. Therefore, we believe these circulating miRNA ratios are novel potential biomarkers for the detection and diagnosis of adenoma and CRC. Previous studies have identified a spectrum of dysregulated miRNAs associated with the tumorigenesis and development of CRC. 10, 24 However, to the best of our knowledge, these studies focused mainly on the miRNAs in tissues or cells. The reliance on surgical resection and invasive procedures for tissue sample collection limits the application of tissue miRNAs in the diagnosis of cancer. Therefore, the goal is to develop a method for the comprehensive analysis of premalignant lesions and cancers through serum miRNA-based biomarkers without the need for biopsy, surgery, or other invasive methods.
Several circulating miRNAs, including miR-21-5p and miR-92a-3p, have been reported as potential biomarkers for the early detection of CRC. [10] [11] [12] [13] [14] [15] Because the normalization of miRNA data in serum samples remains a controversial issue, the use of miRNA ratios has been reported as an easily applicable method for the development of clinically useful signatures based on circulating biomarkers. 23 Several miRNA expression ratios have been identified as diagnostic markers for different cancers, such as lung cancer, bladder cancer, and head and neck cancer. 23, [25] [26] [27] However, to the best of our knowledge, miRNA expression ratios have not been reported in CRC.
The results of the current study demonstrated several miRNA ratios that could act as early detection markers for CRC and adenoma.
Consistent with the findings of the current study, the majority of these miRNAs have been reported previously to be significantly dysregulated in CRC and to play Figure 3 . Receiver operating characteristic curve analysis using serum microRNA (miRNA) ratios to differentiate patients with adenoma from healthy controls and patients with colorectal cancer (CRC). (A) Levels of 3 miRNA ratios (miR-17-5p/miR-135b, miR-92a-3p/miR-135b, and miR-451a/miR-491-5p), which differentiated patients with adenoma from healthy controls. (B) Levels of 5 miRNA ratios (let-7b/miR-367-3p, miR-130a-3p/miR-409-3p, miR-148-3p/miR-27b, miR-148a-3p/miR-409-3p, and miR-21-5p/miR-367-3p), which differentiated patients with CRC from patients with adenoma. AUC indicates area under the receiver operating characteristic curve.
important roles in tumor development. Expression levels of miR-17-5p, miR-135b, miR-92a-3p, miR-21-5p, and miR-148a-3p have been confirmed to be significantly higher in CRC tissues compared with normal tissues. 24 MiR-17-5p is an important regulator of the cell cycle, targeting CDKN1A (P21) and TP53. 28, 29 Increased expression of miR-135b, similar to that of miR-17-5p, has been reported previously to be an important early event in colon carcinogenesis. 30, 31 MiR-135b targets the 3 0 -untranslated region of APC, suppresses its expression, and acts as a downstream effector of oncogenic pathways in colon cancer. 32 It has been reported that miR-92a-3p plays a central role in the development and progression of CRC and in regulation of its aggressiveness. 33 This miRNA downregulates the proapoptotic protein Bim, and its overexpression is significantly related to lymph node metastasis in patients with CRC. 33 Several studies have reported that plasma miR-21-5p could be used as a biomarker for the early detection of CRC. 17 Levels of miR-409-3p have been shown to be significantly lower in CRC tissues compared with adjacent nontumor tissues, and reduced miR-409-3p expression was correlated with CRC metastasis. 34 In addition, miR-409-3p suppresses CRC cell proliferation, in part by inhibiting autophagy mediated by Beclin-1. 35 Similar to miR-409-3p, miR491functions as a tumor suppressor and is downregulated in CRC. 24 In the CRC cell line DLD-1, miR-491 inhibits Bcl-XL expression and induces apoptosis. 36 To gain insight into the potential functional importance of the miRNAs comprising these miRNA ratios, we retrieved their target genes and analyzed their related pathways using miRsystem. The 5 miRNAs included in the 3 miRNA ratios that are capable of differentiating patients with adenoma from healthy controls are likely key regulatory factors of oncogenic processes. The majority of the pathways are related to metabolism, such as metabolism of amino acids and their derivatives, glycerolipid metabolism, and integration of energy metabolism (Table 3) . Metabolic reprogramming is a major hallmark of cancer, which is characterized by upregulated glycolysis, glutaminolysis, lipid metabolism, the pentose phosphate pathway, and mitochondrial biogenesis, among others. 37, 38 These metabolic programs provide cancer cells with not only energy sources but also vital metabolites to support large-scale biosynthesis, continuous proliferation, and other major processes of tumorigenesis. 39, 40 The miRNAs regulate cell metabolic processes through complicated mechanisms, including direct targeting of key enzymes or transporters of metabolic processes and regulating transcription factors, and multiple oncogenic signaling pathways. 41, 42 The participation of the 5 miRNAs in several different metabolic pathways has been supported by several studies, 43, 44 indicating their important regulatory role in CRC development, especially in the early stages of tumorigenesis. The functional mechanisms of these miRNAs in CRC tumorigenesis remain to be elucidated by biological experiments. With regard to the 7 miRNAs included in the 5 miRNA ratios that could differentiate patients with CRC from patients with adenoma and healthy control groups, signal pathway analysis by miRsystem revealed that the majority of these miRNAs are involved in crucial signaling pathways, particularly inflammation-related pathways such as the chemokine signaling pathway and the cytokine-cytokine receptor interaction pathway (Table  4) . It is widely believed that chronic inflammation creates a favorable environment for tumor initiation, promotion, and progression. 37, 45, 46 Cytokines, chemokines, and matrix-degrading enzymes produced during chronic inflammation may damage DNA and/or alter cell proliferation or survival, thereby promoting oncogenesis. Immune cells, which often infiltrate tumors and preneoplastic lesions, also produce a variety of cytokines and chemokines that form a localized inflammatory microenvironment and enhance premalignant cell growth and survival by activating signaling pathways such as nuclear factor kappa beta (NF-jB) or mitogen-activated protein kinases (MAPKs). 47, 48 Several studies to date have reported some of these 7 identified miRNAs as being involved in the regulation of inflammation and cancer development. 49, 50 Moreover, these miRNAs participate in several other cancer-related pathways, including direct P53 effectors, the natural killer T cell and DNA repair pathways, and cell cycle checkpoints, which indicates their important role in CRC development.
The current study did have some limitations. We did not obtain information regarding a history of colorectal adenoma or endoscopy checkup for the control subjects; therefore, it is possible some participants might have had adenomas or a history of adenomas. Nevertheless, this confounding effect should bias the results toward the null. The relatively small cohorts of patients with CRC, patients with adenoma, and healthy control subjects Abbreviations: APC/C, anaphase promoting complex/cyclosome; ATF-2, activating transcription factor 2; CRC, colorectal cancer; GPCR, G protein-coupled receptor; KEGG, Kyoto Encyclopedia of Genes and Genomes; miRNA, microRNA; NKT, natural killer T cell. Analyzed with let-7b, miR-367-3p, miR-130a-3p, miR-409-3p, miR-148-3p, miR-27b, and miR-21-5p. a Immune-related pathways are shown in bold font. b Empiric P values were compared with 1000 random selections.
prevented us from conducting stratified analyses by clinical and epidemiologic factors and adjusting for multiple comparisons. The small sample size of the discovery set in the current study also might have limited our power to identify more differentially expressed miRNAs during the screening stage. In addition, due to the use of different gene expression platforms, we could not merge the data from the discovery and validation sets. Future studies using large, independent prospective cohorts are needed to validate the current study findings for clinical practice. We conducted a systematic investigation to identify circulating miRNA biomarkers for the early detection of CRC. We identified 3 miRNA ratios that effectively distinguish patients with precancerous adenoma from healthy controls and 5 miRNA ratios that distinguish patients with CRC from those with benign adenoma and healthy controls. The evaluation of miRNA signatures as ratios and functional enrichment analysis of their putative targets demonstrated potential etiologic mechanisms and supported the miRNAs identified as candidate early detection markers for adenoma and CRC. Further functional investigations of miRNA gene targets in tumor tissues also are warranted to explore the mechanisms underlying the progression of CRC from normal tissue to precancerous adenoma and ultimately malignancy. 
